<DOC>
	<DOCNO>NCT01012960</DOCNO>
	<brief_summary>The purpose study evaluate opioid-induced effect pharynx esophagus centrally peripherally mediate .</brief_summary>
	<brief_title>Opioids Esophageal Function</brief_title>
	<detailed_description>Opioids induce pharyngeal esophageal dysfunction reduce low esophageal sphincter ( LES ) pressure , thereby decrease barrier pressure stomach esophagus . This contribute increase risk regurgitation aspiration anaesthesia induction postoperative period , patient treat opioids pain relief . The effect opioid antagonist opioid induced pharyngeal dysfunction lower esophageal sphincter pressure unknown . Therefore great clinical value evaluate negative effect reverse peripheral opioid antagonist , methylnaltrexone . Methylnaltrexone one new agent peripherally act opioid antagonist act reverse side effect opioid drug , constipation , without affect analgesia . If opioid induce pharyngeal esophageal dysfunction reduction lower esophageal sphincter pressure peripherally induce mediate via peripheral opioid receptor , methylnaltrexone might reverse effect thereby reduce postoperative morbidity reduce pulmonary complication . On hand , dysfunction centrally induce mediate via peripheral opioid receptor effect methylnaltrexone . The pharyngeal esophageal motility/function register easy objective way high resolution manometry , ManoScan 360 . ManoScan 360 equipment 36 sensor 1 cm space 12 tip transducer every sensor . The 36 closely spaced sensor automatically capture relevant motor function pharynx stomach . The system collect reliable consistent data record improve diagnostic accuracy , data analyze use ManoView analyze software . ManoScan 360 CE mark approval use Ã–rebro University Hospital last two year .</detailed_description>
	<mesh_term>Esophageal Diseases</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>18 40 year old healthy volunteer sex . sign date Informed Consent . willing able comply protocol duration trial . anamnesis pharyngoesophageal dysfunction . know history cardiac , pulmonary neurological disease . ongoing medication . allergy history reaction methylnaltrexone , remifentanil fentanyl analogue . pregnancy breast feeding . participation another clinical medicinal trial last 30 day followup complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>methylnaltrexone</keyword>
	<keyword>upper esophageal sphincter</keyword>
	<keyword>low esophageal sphincter</keyword>
	<keyword>high resolution solid state manometry</keyword>
	<keyword>opioid induce pharyngeal esophageal dysfunction</keyword>
</DOC>